- Phase I data does not prove effectiveness of SELINEX, and leaves many questions unanswered.
- June secondary offering of 2,844,334 share dilution and insider selling of 220,000 shares @ $42.50 following 100% runup on questionable Phase I data.
- IPO was only nine months ago at $16 share.
- CEO and CSO's last company Epix Pharmaceuticals went from NASDAQ to OTC to bankruptcy and liquidation.
- 2013 revenues were only $233,000 for this biotech currently valued well over $1 billion.